Patents Examined by Claire M. Kaufman
  • Patent number: 6096873
    Abstract: A novel member of the heregulin superfamily has been identified which is designated ".gamma.-HRG". This molecule, secreted by human breast cancer MDA-MB-175 cells, leads to the formation of a constitutive active receptor complex and stimulates the growth of these cells in an autocrine manner. .gamma.-HRG polypeptide and nucleic acid are disclosed, together with various uses therefor (e.g. use of .gamma.-HRG nucleic acid for the recombinant production of .gamma.-HRG). .gamma.-HRG antagonists (e.g. neutralizing antibodies and antisense nucleic acid molecules) as well as uses therefor are also described.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: August 1, 2000
    Assignee: Genentech, Inc.
    Inventors: Gabriele Maria Schaefer, Mark Sliwkowski
  • Patent number: 6096865
    Abstract: The present invention relates to mutants of the green fluorescent protein having improved fluorescent properties at 37.degree. C. The mutants provide for improved methods of monitoring gene expression, e.g., for use as cell markers or protein expression indicators in prokaryotic and, especially, eucaryotic systems where the standard physiological temperature is 37.degree. C.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: August 1, 2000
    Assignee: Amgen Inc.
    Inventor: Mark Michaels
  • Patent number: 6090922
    Abstract: The present invention relates to nucleotide sequences of the human Notch and Delta genes, and amino acid sequences of their encoded proteins, as well as fragments thereof containing an antigenic determinant or which are functionally active. The invention is also directed to fragments (termed herein "adhesive fragments"), and the sequences thereof, of the proteins ("toporythmic proteins") encoded by toporythmic genes which mediate homotypic or heterotypic binding to toporythmic proteins. Toporythmic genes, as used herein, refers to the genes Notch, Delta, and Serrate, as well as other members of the Delta/Serrate family which may be identified, e.g., by the methods described herein. Analogs and derivatives of the adhesive fragments which retain binding activity are also provided. Antibodies to human Notch and to adhesive fragments are additionally provided.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: July 18, 2000
    Assignee: Yale University
    Inventors: Spyridon Artavanis-Tsakonas, Richard Grant Fehon, Ilaria Rebay
  • Patent number: 6087115
    Abstract: The present invention is directed to a constitutively active G protein coupled receptor of human herpesvirus 8, as well as a method of identifying negative antagonists of a constitutively active G protein coupled receptor. The method comprises co-expressing in a host cell a constitutively active G protein coupled receptor and a reporter protein, wherein expression of the reporter protein is controlled by a promoter responsive to a signalling pathway activated by the constitutively active G protein coupled receptor; exposing the host cell to a test substance; and determining a level of reporter protein activity, wherein the level of reporter protein activity indicates effectiveness of the test substance as a negative antagonist of the constitutively active G protein coupled receptor. The invention further provides a method of preventing tumor formation or cell proliferation caused by a constitutively active G protein coupled receptor.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: July 11, 2000
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Marvin C. Gershengorn, Leandros Arvanitakis, Elizabeth Geras-Raaka, Ethel Cesarman
  • Patent number: 6077825
    Abstract: The invention is drawn to anti-thrombin proteins from the salivary glands of the species, Simulium. Methods for recombinant production of the protein as well as biomedical uses are provided.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: June 20, 2000
    Assignee: Auburn University
    Inventors: Mary S. Cupp, Eddie W. Cupp
  • Patent number: 6074873
    Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligand homologues NL2, NL3 andNL6 (FLS139), the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: June 13, 2000
    Assignee: Genentech, Inc.
    Inventors: Sherman Fong, Napoleone Ferrara, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Kenneth Hillan, P. Mickey Williams
  • Patent number: 6074862
    Abstract: Compositions and methods are provide for potentiating the activity of the mitogen-activated protein kinase p38. In particular the mitogen-activated protein kinase kinase MEK6, and variants thereof that stimulate phosphorylation of p38 are provided. Such compounds may be used, for example, for therapy of diseases associated with the p38 cascade and to identify antibodies and other agents that inhibit or activate signal transduction via p38.
    Type: Grant
    Filed: December 20, 1995
    Date of Patent: June 13, 2000
    Assignee: Signal Pharmaceuticals Inc.
    Inventors: Bernd Stein, Maria X. H. Yang
  • Patent number: 6072031
    Abstract: The cDNA and amino acid sequences for a cellular apoptosis susceptibility (CAS) protein are used to detect expression and amplification of the CAS gene in normal and cancer cells. An antisense CAS gene sequence introduced into living cells inhibits CAS protein activity and thus prevents or inhibits apoptosis in the cells.
    Type: Grant
    Filed: August 21, 1997
    Date of Patent: June 6, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ira Pastan, Ulrich Brinkmann
  • Patent number: 6057435
    Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5, NL8, and NL4, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.
    Type: Grant
    Filed: October 29, 1997
    Date of Patent: May 2, 2000
    Assignee: Genentech, Inc.
    Inventors: Paul J. Godowski, Austin L. Gurney
  • Patent number: 6057091
    Abstract: The present invention provides two novel polypeptides, referred to as the "N" and "C" fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G.sup..dwnarw. CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described.
    Type: Grant
    Filed: October 7, 1997
    Date of Patent: May 2, 2000
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Philip A. Beachy, Jeffrey A. Porter
  • Patent number: 6057428
    Abstract: The present invention involves the preparation of vascular endothelial growth factor (VEGF) variants which provide materials that are selective in respect to binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.
    Type: Grant
    Filed: August 2, 1996
    Date of Patent: May 2, 2000
    Assignee: Genentech, Inc.
    Inventors: Bruce A. Keyt, Francis Hung Nguyen, Napoleone Ferrara, Brian C. Cunningham, James A. Wells, Bing Li
  • Patent number: 6054289
    Abstract: Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for therapeutic purposes. Antagonist against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides.
    Type: Grant
    Filed: August 30, 1996
    Date of Patent: April 25, 2000
    Assignee: Human Genome Sciences, Inc.
    Inventor: Paul A. Moore
  • Patent number: 6051221
    Abstract: The invention relates to a novel tyrosine kinase designated brk and the use of this tyrosine kinase in the development of diagnostic and therapeutic approaches to cancer. The novel tyrosine kinase was isolated from a human metastatic breast tumor using a PCR based differential screening approach and has the deduced amino acid sequence shown in SEQ ID NO:2.
    Type: Grant
    Filed: June 10, 1996
    Date of Patent: April 18, 2000
    Assignee: Glaxo Wellcome Inc.
    Inventors: Barry Austin Gusterson, Mark Roger Crompton, Philip John Mitchell, Karen Tracey Barker, Taherah Kamalati, Martin John Page, Paul Spence
  • Patent number: 6046025
    Abstract: The present invention provides a novel method for expression of high levels of heterologous proteins in Drosophila cells.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: April 4, 2000
    Assignee: SmithKline Beecham Corp.
    Inventors: Hanne Ranch Johansen, Ariane Adrienne Van Der Straten-Ponthoz, Martin Rosenberg
  • Patent number: 6040290
    Abstract: The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays. The present invention also pertains to a method for inhibiting the growth of adenocarcinoma cells.
    Type: Grant
    Filed: August 26, 1996
    Date of Patent: March 21, 2000
    Assignee: Georgetown University
    Inventors: Marc E. Lippman, Ruth Lupu
  • Patent number: 6040175
    Abstract: Described herein are isolated polynucleotides which code for an AMPA-type human CNS glutamate receptor, designated the human GluR2B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing these receptor is disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 21, 2000
    Assignee: Allelix Biopharmaceuticals, Inc.
    Inventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt
  • Patent number: 6033865
    Abstract: In accordance with the present invention, there are provided nucleic acids encoding human NMDA receptor protein subunits and the proteins encoded thereby. The NMDA receptor subunits of the invention comprise components of NMDA receptors that have cation-selective channels and bind glutamate and NMDA. In one aspect of the invention, the nucleic acids encode NMDAR1 and NMDAR2 subunits of human NMDA receptors. In a preferred embodiment, the invention nucleic acids encode NMDAR1, NMDAR2A and NMDAR2C subunits of human NMDA receptors. In addition to being useful for the production of NMDA receptor subunit proteins, these nucleic acids are also useful as probes, thus enabling those skilled in the art, without undue experimentation, to identify and isolate related human receptor subunits.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 7, 2000
    Assignee: Sibia Neurosciences, Inc.
    Inventors: Lorrie P. Daggett, Steven B. Ellis, Chen Wang Liaw
  • Patent number: 6031076
    Abstract: The present invention relates to the discovery of novel conservin genes and polypeptides. Therapeutics, diagnostics and screening assays based on these molecules are also disclosed.
    Type: Grant
    Filed: January 5, 1998
    Date of Patent: February 29, 2000
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventors: Dean A. Falb, Carlos J. Gimeno
  • Patent number: 6030831
    Abstract: The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: February 29, 2000
    Assignee: Genetech, Inc.
    Inventors: Paul J. Godowski, Austin L. Gurney
  • Patent number: 6027921
    Abstract: Chimeric proteins, which comprise a ligand-binding domain of a first receptor and a carrier domain which binds a cell surface receptor other than the first receptor, useful in transporting a selected substance present in extracellular fluids, such as blood or lymph, into cells; quantitative assays for the selected substance using chimeric proteins; DNA encoding the chimeric proteins; plasmids which contain DNA encoding the chimeric proteins; mammalian cells, modified to contain DNA encoding the chimeric proteins, which express and, optionally, secrete the chimeric proteins; a method of producing the chimeric proteins; a method of isolating the chimeric proteins; a method of using the chimeric proteins to assay the selected substance; and a method of reducing extracellular levels of the selected substance through administration of the chimeric protein, which results in transport of the selected substance into cells.
    Type: Grant
    Filed: March 9, 1998
    Date of Patent: February 22, 2000
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Michael W. Heartlein, Jeffrey F. Lemontt, Michael F. Concino